Brain-extraction Dice
0.97 Dice
- EndpointBrain-extraction segmentation overlap
- Population362 manually annotated neurological MR volumes
- Tested versionNeuro Insight V1.0 brain-extraction module described in K243681; build not stated
Authorized purpose: Neuro Insight V1.0 assists trained professionals analyzing neurological MRI through NeuroPro maps/metrics and optional Neuro Synchronizer viewing, comparison, and parameter editing in compatible DICOM integration environments; it does not alter original images or replace diagnosis.
Overview status: Source-reviewed overview
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
Clinical takeaway. Clinical role: Neuro Insight V1.0 assists trained professionals analyzing neurological MRI through NeuroPro maps/metrics and optional Neuro Synchronizer viewing, comparison, and parameter editing in compatible DICOM integration environments; it does not alter original images or replace diagnosis.
Evidence takeaway. Evidence from the reviewed source record: The FDA packet describes brain-extraction module validation on 362 manually annotated MR volumes across five-fold cross-validation; this is a submodule evaluation, not an end-to-end clinical outcome study of Neuro Insight.
Evidence context not reviewed for this FDA record.
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Packet wording: "Both Neuro Insight V1.0 and Olea Sphere® V3.0 are user-defined software analysis tools used for the analysis of magnetic resonance imaging (MRI) studies. Both devices are intended for use in Clinical/Hospital Environment, by any trained professional." … "It is intended to assist appropriately trained medical professionals in their analysis workflow on neurological MRI images.". Read from the exact FDA decision document on 2026-11-14.
Evidence
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
This field has not been curated yet.
This field has not been curated yet.
0.97 Dice
K243681
This metric is limited to a brain-extraction subcomponent and should not be read as end-to-end product diagnostic performance.
Safety and lifecycle
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Price not public here; enter your quote
Not verified: Pricing information is recorded but not verified against a resolving source.
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Source context, not route validation: Multiphase or monophase neurological MR images in DICOM, including FLAIR, T1, T2, T1g, diffusion (DWI), and DSC perfusion series.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Field checked 2026-09-06 · FDA 510(k) K243681: Neuro Insight V1.0
Source context, not route validation: NeuroPro can be integrated and deployed through a technical integration environment responsible for transferring, storing, converting, and displaying DICOM data; Neuro Synchronizer can be integrated with compatible environments.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Field checked 2026-09-06 · FDA 510(k) K243681: Neuro Insight V1.0
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-11-14 ·
Source context, not route validation: Parametric maps and metrics including ADC, CBF, CBV, corrected CBV, K2, MTT, TTP, Tmax/Delay, and tMIP, plus intra- and inter-exam co-registration and optional viewing/comparison through Neuro Synchronizer.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Field checked 2026-09-06 · FDA 510(k) K243681: Neuro Insight V1.0
Unresolved route: Parametric maps and metrics including ADC, CBF, CBV, corrected CBV, K2, MTT, TTP, Tmax/Delay, and tMIP, plus intra- and inter-exam co-registration and optional viewing/comparison through Neuro Synchronizer.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Field checked 2026-09-06 · FDA 510(k) K243681: Neuro Insight V1.0
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
No tests below have been performed or accepted.
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact submission describes NeuroPro integration with an environment that transfers, stores, converts, and displays DICOM imaging data, with optional Neuro Synchronizer viewing and parameter editing.
exact submission · checked 2026-09-06Olea's official Neuro INSIGHT page describes web-based access without installation on the reading station and standard PACS/RIS integrations; the current deployed configuration and exact submission build require confirmation.
product family · checked 2026-09-07Regulatory identity
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
Research record
This audit distinguishes completed source review from fields that have not yet been researched.
No stored PubMed or ClinicalTrials.gov candidate identifiers for this submission in the 2026-09-01 snapshot; exact-submission recall candidate review was also zero. This metadata screen is not a full paper review. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, literature index, trial registry, fda device recall, pubmed, clinical trials, openfda device recall
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
No public amount, range, currency, geography, or contract term was established.
Bounded web search on 2026-10-26 (query: "Olea Medical Neuro Insight reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. This records what was found, not that none exists; eligibility depends on payer, site of service and use case.
The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.
No scoped current security, data-flow, access-control, retention, or incident-response documentation was established.
Current onboarding, competency, and support commitments were not established.
Local acceptance testing, production monitoring, update control, and drift review were not established.
7 sources - 3 history items
Scope: identity, purpose, clinicalUse, modality, anatomy, input, output, limitations, integration, evidenceSummary, evidenceMetrics, evidenceStudies
Scope: regulatoryIdentity, modalityContext
Scope: intendedUsers, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities
Scope: evidenceDiscovery
Scope: evidenceDiscovery, studyStatus
Scope: recallDiscovery, nativeSubmissionMatching
Scope: productFamilyWorkflow, implementationCapabilities
Regulatory record
510(k)
Research record
human reviewed
Editorial review
Source-reviewed editorial overlay
Alternatives
Imeka Solutions, Inc.
Authorized purpose: ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained medical professionals; it does not predict, diagnose or interpret brain health.
BeauBrain Healthcare, Inc.
Authorized purpose: Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it is adjunctive and not the sole basis for final decisions.
Siemens Healthcare GmbH
Authorized purpose: Brain MRI morphometry and white matter hyperintensity quantification, including normative comparison and longitudinal change assessment for clinician review.
Hyperfine, Inc.
Authorized purpose: Swoop Portable MR Imaging System provides ultra-low-field point-of-care head MRI for all ages and includes deep-learning T1, T2, FLAIR, and DWI reconstruction.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Open existing correction destinationPermission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.
Correction policy and limits · Public repository change history